Pitt Researchers Identify Protein That Plays Key Role In Pulmonary Emphysema Development

Main Category: COPD
Also Included In: Biology / Biochemistry
Article Date: 26 Feb 2009 - 7:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Scientists at the University of Pittsburgh School of Medicine are blazing a trail down a molecular pathway that could lead to new treatments, and perhaps even prevention strategies, for the lung disease emphysema.

Their new study, which appears in the Feb. 27 issue of the Journal of Biological Chemistry, indicates that blocking the activity of a structural protein called caveolin-1 stops free radical-induced aging and damage of fibroblasts, a kind of lung cell, in an animal model of emphysema.

Emphysema typically occurs after long periods of cigarette smoking. Toxins in the smoke destroy the walls of the alveoli, the tiny air-filled sacs in lung tissue where oxygen exchange happens, impairing lung function and ultimately leading to death due to respiratory failure.

"It was thought that smoking-induced lung inflammation was the main reason for destruction of alveoli," said senior investigator Ferruccio Galbiati, Ph.D., associate professor of pharmacology and chemical biology at the Pitt School of Medicine. "Our findings indicate that the free radicals or oxidants produced by smoking accelerate the aging of lung fibroblasts, which may contribute to the pathogenesis of emphysema."

Cells cannot replicate forever, he explained. After a certain number of divisions, the cycle stops due to a cellular aging process called senescence. Oxidative stress, meaning increased production of free radicals, can induce that process prematurely.

In Dr. Galbiati's study, normal mice began to show signs of premature aging in lung fibroblasts after six weeks of exposure to cigarette smoke and developed pulmonary emphysema after six months. But premature senescence and emphysema induced by smoke exposure were significantly prevented in mice that lacked the gene to make caveolin-1.

"For our next step, we would like to identify drugs that can reduce the amount of caveolin-1 to see if they affect emphysema development," Dr. Galbiati said. "That way, we might be able to slow down or perhaps prevent some of the lung damage that smoking causes."

The research was supported by a grant from the National Institutes of Health.

The University of Pittsburgh School of Medicine is one of the nation's leading medical schools, renowned for its curriculum that emphasizes both the science and humanity of medicine and its remarkable growth in National Institutes of Health (NIH) grant support, which has more than doubled since 1998. For fiscal year 2007, the University ranked sixth out of more than 3,000 entities receiving NIH support with respect to the research grants awarded to its faculty. As one of the university's six Schools of the Health Sciences, the School of Medicine is the academic partner to the University of Pittsburgh Medical Center (UPMC). Their combined mission is to train tomorrow's health care specialists and biomedical scientists, engage in groundbreaking research that will advance understanding of the causes and treatments of disease and participate in the delivery of outstanding patient care.

University of Pittsburgh Medical Center